2016 issue 1


Volume 32, issue 1

Review article

Doksylamina w leczeniu zaburzeń snu i lęku / Doxylamine in the treatment of sleep disturbances and anxiety

Marek Krzystanek1, Anna Białek1, Artur Pałasz2, Rafał Skowronek3
1. Śląski Uniwersytet Medyczny w Katowicach, Katedra Psychiatrii i Psychoterapii, Klinika Rehabilitacji Psychiatrycznej
2. Śląski Uniwersytet Medyczny w Katowicach, Zakład Histologii, Katedra Histologii i Embriologii
3. Śląski Uniwersytet Medyczny w Katowicach, Katedra Medycyny Sądowej i Toksykologii Sądowo-Lekarskiej
Farmakoterapia w Psychiatrii i Neurologii 2016, 32 (1), 41–47
Date of publication: 16-05-2016
DOI: http://dx.medra.org/10.17393/fpn.2016.04.003
Keywords: doksylamine, antihistaminergic drugs, sleeping pills, sedative drugs


Doksylamine is the inquiring proposal, facing the limited number of the safe and effective sedative and sleeping drugs. Doxylamine belongs to the first-generation H1-antihistamine group. It shows sedative, sleep-inducing, antiemetic and anti-allergic effect.

The aim of the article was to compare doxylamine with other sleeping pills and tranquilizers. The detailed research was performed to investigate effectiveness and tolerance of doxylamine in the treatment of insomnia and anxiety. The potency of the sedative effect of doxylamine, flunitrazepam and fenobarbital are comparable, but doxylamine does not cause addiction. Numerous studies prove the effectiveness and safety of doxylamine in the short-term treatment of insomnia. The safety of doxylamine in pregnancy was also proven. The therapeutic index of doxylamine is wide, and its potential side effects are usually mild and transient. Most common adverse effects are daytime sleepiness and dry mouth.

The collected data indicate the doxylamine as an alternative to sleep-inducers and tranquilizers.

Address for correspondence:
Klinika Rehabilitacji Psychiatrycznej
Śląski Uniwersytet Medyczny w Katowicach
ul. Ziołowa 45, 40-635 Katowice, Poland
phone: +48 32 20 59 260
email: krzystanekmarek@gmail.com